➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ FDA approves new ocular surface anesthesia gel ➤ New drop approved to reduce IOP ➤ Newly available IOL incorporates technology that minimizes visual disturbances ➤ Interim data from Phase 1 trial for intravitreal implant to treat AMD ➤ Multiparty financing solution brought to ophthalmic practices ➤ Complimentary access to video journal ➤ ASCRS news and events
IOP elevation following intravitreal injections can be divided into short-term and long-term elevations. Short-term elevations are common, and some studies have estimated that they affect greater than 90% of patients.
➤ Machine assesses cardiovascular risk with retinal scan ➤ FDA requests more info for BLA for bevacizumab ➤ Genetic variables affect NMOSD treatment ➤ Study: 12-month results from canaloplasty-trabeculotomy procedure ➤ Topline results from Phase 3 pivotal trial evaluating pupil-modulating drug ➤ ASCRS news and events
➤ Topline results from Phase 3 pivotal trial evaluating mydriasis drug ➤ First person dosed in Phase 3 trial for first-in-class dry eye candidate ➤ Phase 2 study of a novel glaucoma drop targeting non-traditional outflow ➤ Digital vision screening platform with machine learning ➤ Alcon to acquire dry eye drop and inflammation/pain drop ➤ New issue online ➤ ASCRS news and events
➤ FDA approves new ICL ➤ Home tonometer receives 510(k) clearance ➤ First patient treated in what will be the largest standalone MIGS clinical trial ➤ Topline results from second Phase 3 trial of mydriasis-reversing drug ➤ ASCRS news and events
➤ FDA clearance for viscodelivery system ➤ FDA approves IND application for immunomodulatory agent for dry eye ➤ Phase 2b results for sustained-release, IOP-lowering implant ➤ Positive topline Phase 2 results for investigational dry eye drug ➤ Phase 2 trials begin for two transdermal drug formulations ➤ Second pivotal trial begins for wet AMD gene therapy ➤ Alcon completes acquisition of Ivantis ➤ ASCRS news and events
➤ FDA approves first prescription eye drop for presbyopia treatment ➤ Primary endpoint reached in Phase 2 trial for dry eye disease drug ➤ New type of retinal nerve cell discovered ➤ Companies enter collaboration to develop an oral DME, wet AMD treatment ➤ iCare USA acquires remote patient-monitoring tech company ➤ ASCRS news and events
➤ Phase 3 clinical trial results for once-daily netarsudil ophthalmic solution ➤ Dexamethasone ophthalmic insert approved for new indication ➤ Results from home OCT feasibility study ➤ FDA accepts application for brolucizumab for DME ➤ Companies form alliance to develop nomograms, lens constants and astigmatism calculations ➤ AAO announces next CEO ➤ ASCRS news and events
➤ Combination pharmaceutical therapy being investigated for presbyopia meets study endpoints ➤ Positive results in Phase 2 clinical trial for IOP-lowering agent ➤ Phase 3 results from study of gene therapy for retinal neurodegenerative diseases ➤ Positive safety results in Phase 1 anti-VEGF treatment ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.